Six Bidders Vie for Shafa Darou Management Block; Base Price Reaches 50,000 Billion Tomans

Six groups, including Golrang Pharmaceutical Group, Behestan Darou, the Social Security Fund for Farmers, Villagers and Nomads, and the Farzadnia family, have entered the competition to purchase the management block of Shafa Darou Investment Holding. The tender has a base value of around 50,000 billion tomans and could change the ownership structure of one of the country's major pharmaceutical companies.

Six companies, including Gulrang Pharmaceutical Group, Behestan Daru, Social Insurance Fund of Farmers, Villagers and Nomads and Farzadenia Family have entered the competition to buy the management block of Shefadaro Investment Holding. An auction with a base value of about 50 thousand billion tomans that can change the composition of ownership of one of the important collections of the country's pharmaceutical industry.

Six contenders, including Golrang, Behestan Daru and the Farzadenia family, have entered the competition for the purchase of Shafadaro's management block with a base value of 50 thousand billion tomans. An auction that can change the equations of ownership of one of the largest pharmaceutical holdings in the country.

According to the report of Ambassador Arjan, quoted by Salem Khabar, a few days before the auction of the management block of Shefadaro Investment Holding, there are signs of the formation of a serious competition between a group of investment actors, pharmaceutical groups and private sector investors. A competition that, considering the base value of about 50 thousand billion tomans of the block, can become one of the important and news-making transactions of the country's capital market and pharmaceutical industry.

Based on the information presented about the applicants of this auction, six groups including Social Insurance Fund of Farmers, Villagers and Nomads, Golrang Pharmaceutical Group, Behestan Daru Group represented by Nasser Riahi and Homayun Farzaneh, Zagros Daru Parsian Group represented by Hossein Sayadi, Khesht Dej Ilia Group represented by Farshad Dehghani and Pars Tire Group owned by the Farzadenia family are in the list of players of this competition.

The variety of applicants, from institutional investors to groups active in the pharmaceutical industry and economic groups with industrial backgrounds, shows that the Shafa Daru auction is not just a stock transaction; Rather, it is a competition to control and exploit the capacities of one of the most important sets of drug production and distribution in the country.

social insurance fund for farmers, villagers and nomads; Institutional investor in 50-member competition

The presence of the social insurance fund of farmers, villagers and nomads in this competition is significant from the point of view of institutional investment. This fund, with its social mission and the necessity of managing its resources and reserves, should strike a balance between economic returns, investment risk, and resource conservation requirements.

The entry of an institutional investor into the competition for Shafa Daro makes the financial and strategic aspects of this auction more prominent; Especially, the base value of the block will make financing and accurate evaluation of investment returns one of the determining factors.

Saffron medicinal group; A competitor with the support of presence in the drug and health chain

Golrang Industrial Group is one of the large multidisciplinary groups of the private sector of the country, which operates in various fields, from consumer goods to medicine and health. The pharmaceutical activities of this group have provided a basis for exploring development opportunities in the drug production and supply chain.

Golrang's entry into Shafa Daro's competition is important because the acquisition of a large pharmaceutical holding can create opportunities to expand the scale of activity, strengthen the supply chain, and take advantage of joint capacities, if the deal is realized and there are economic synergies.

In case of serious participation of this group in the competition, the ability to finance and its assessment of the economic value of assets and the profitability capacity of Shafa Daro will be important factors in determining the auction path.

Behestan Daru Group; The presence of well-known faces of the pharmaceutical industry

Behestan Daru Group, represented by Nasser Riahi and Homayun Farzaneh, is another prominent name in the list of applicants. The presence of a group with a history of activity in the pharmaceutical industry raises the possibility that the evaluation of production capacities, product portfolio, market network and the possibility of synergy between businesses are important in its economic calculations.

For a pharmaceutical actor, Shafa Daru can be examined from the perspective of developing the activity portfolio and access to production and commercial capacities. In such a situation, the potential buyer's operational and specialized advantages, along with financial strength, can affect his assessment of the block's value.

Zagros Daru Parsian Group; Entered by Hossein Sayadi

Zagros Daru Parsian Group, represented by Hossein Sayadi, has also been introduced among the collections in the competition. The presence of this group alongside the biggest players in the pharmaceutical and investment industry shows that the range of applicants is not limited to one type of investor.

In an auction of this size, the financing capacity, partnership structure, investment horizon, and group's asset utilization plan, along with the evaluation of the block's economic value, can be decisive in the final decision of each applicant.

clay group of Dej Ilia; Representation of Farshad Dehghani in the great Shafa Daru competition

Eight Forts of Ilia Group, represented by Farshad Dehghani, is another group whose name has been mentioned in the list of applicants. The presence of this group in a competition with a base value of around 50 Hamat emphasizes the importance of examining the financial capacity, investment structure and potential plan of the buyer to manage a large pharmaceutical complex.

Considering the financial aspects of the transaction, just being on the list of applicants does not mean a definite decision to buy; However, the entry of this collection along with other applicants adds to the diversity of actors in this auction.

Pars Tire Group and Farzadenia Family; The return of the winner of the previous auction to the field of competition?

One of the remarkable points in the upcoming Shafa Daru auction is the re-appearance of Pars Tire Group belonging to the Farzadnia family; A family who, according to the information presented, had won the title in the previous auction, but the deal did not reach the stage of certainty and finalization.

Now, the presence of this group again in the competition for the management block of Shafa Daro raises the question whether the Farzadenia family has entered the field this time with the aim of finalizing the deal and completing the process that was not completed in the previous period?

Considering the significant increase in the base price of the block from about 15 hemats in the previous auction to about 50 hemats in the new auction, the reappearance of the previous winner along with other applicants can be one of the attractive axes of this competition. Of course, the final goal of this group's re-appearance and its decision about the proposed price is not certain until the official announcement and clarification of the auction result.

The importance of the upcoming auction becomes clearer when its figures are compared with last year's conditions. In the previous auction, the price of each share of Shafa Daro was about 6 thousand tomans and the value of the entire block was about 15 hemats. Now the basic price of each share has reached about 20 thousand tomans and the basic value of the block has reached about 50 hemats.

In this way, the base price of each share and the base value of the block have both tripled; A change that, along with the increase in the market value of the holding itself from the range of 3 to 3.5 hemats to around 20 to 21 hemats, presents a different picture of the valuation of this group compared to last year.

This change took place in a situation where, according to the announced performance figures, the collective sales of the group companies in the 9 months of the reported period reached about 21 hemt, while the sale of the same period last year was about 6.5 hemt.

Also, the group's gross profit has grown by 334% to about 14 hemats, operating profit has increased by 315% to about 11.5 hemats and net profit has reached about 8.6 hemats with a 455% growth.

The improvement of indicators such as the ratio of cost to sales, the ratio of expenses to sales and the ratio of financial expenses to sales are among the factors mentioned in explaining the growth of the group's profitability. The set of these developments has increased the market's attention to the operational and financial capacities of Shafa Daro.

In analyzing the performance of a large pharmaceutical holding, the increase in market value becomes more fundamentally important when it is accompanied by sales growth, profitability improvement, and operational indicators improvement. The figures announced about Shafa Daru also show that the growth of the market value in the recent period has coincided with significant changes in the financial performance of the group.

Modifying operational processes, paying attention to key performance indicators, controlling costs, strengthening financial discipline and using expert managers are among the factors that can contribute to improving the performance of subsidiary companies. In a multi-company complex, coordination between the holding and subsidiaries and setting clear goals for production, sales and profitability can lead to better use of existing capacities.

From this point of view, Shafa Daro's recent performance can be seen as a test to measure the effectiveness of performance-oriented management and process improvement; A test whose final result should be determined in the continuation of sales growth, profit quality, cash flow and competitiveness of the group companies in the coming periods.

According to the presented figures, the total market value of Shafa Daru and its subsidiaries has also increased from about 16 hemat last year to about 92 hemat; However, this index is different from the market value of the holding itself and should not be combined with it.

Now the main question of the market is whether the presence of six collections with different natures and backgrounds will lead to competition beyond the base price or not. The answer to this question depends on the applicant's ability to finance, their assessment of the economic value of the assets, the terms of payment and their plans for the future of the group.

In a transaction of this size, the value of assets and subsidiary companies is only part of the equation; Debts, working capital, financial obligations, profit quality, cash flow and the requirements of running a large pharmaceutical holding also play a decisive role in buyers' calculations.

However, the presence of groups from the private sector and institutional investors, along with the significant growth of Shafa Daro's financial indicators, has prepared the ground for one of the most important and interesting competitions in the capital market. The history of the Farzadenia family winning the previous auction and their return to the competition has also added to the attractiveness of this event; Especially since this time the base price of the block is more than three times the figure mentioned in the previous period.

The Shafa Daru auction is now not just a competition for a block of 50 hemti; A test to measure the economic value of a pharmaceutical holding is the ability of investors to finance a big deal and their vision of the future of the country's pharmaceutical industry. The result of this competition can provide a clearer picture of the attractiveness of pharmaceutical assets for investors and market expectations of the value of this industry.

A new study shows that people born recently show signs of being biologically older than previous generations of the same age. In other words, a 40-year-old today may have biological characteristics that make him look older than a 40-year-old decades ago.

According to a new study, people who have a habit of eating late at night may be putting their liver health at risk.